Regulatory FDA seeks feedback on voucher program; Study data lift ‘overhang’ on Insmed shares BioPharma DiveIndustry executives can share their views on the national priority program at a June meeting.RegulatoryRead full story pharminent March 24, 2026 BioPharma Dive Industry executives can share their views on the national priority program at a June meeting. Regulatory Read full story Post navigation Previous: NOW AVAILABLE: The 2026 Economic Report on U.S. Pharmacies and Pharmacy Benefit ManagersNext: Immutrin raises $87M to advance drug for progressive heart disease Related Stories Regulatory Third Circuit Affirms Denial of Stelara Biosimilar Injunction pharminent May 11, 2026 Regulatory Partner’s Bizengri cleared by FDA for ultra-rare cancer days after winning priority voucher pharminent May 11, 2026 Regulatory BMS’ Sotyktu secures EC approval for psoriatic arthritis pharminent May 11, 2026
